Compare GHC & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GHC | PTCT |
|---|---|---|
| Founded | 1877 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.5B |
| IPO Year | 1994 | 2006 |
| Metric | GHC | PTCT |
|---|---|---|
| Price | $1,194.73 | $60.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $100.33 |
| AVG Volume (30 Days) | 25.6K | ★ 1.2M |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ 71.04 | 0.90 |
| Revenue | ★ $2,932,099,000.00 | $264,734,000.00 |
| Revenue This Year | $5.98 | N/A |
| Revenue Next Year | $4.03 | $9.47 |
| P/E Ratio | ★ $16.86 | $67.73 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $974.00 | $58.80 |
| 52 Week High | $1,262.35 | $90.87 |
| Indicator | GHC | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 67.83 | 34.61 |
| Support Level | $1,104.70 | N/A |
| Resistance Level | $1,221.02 | $68.93 |
| Average True Range (ATR) | 24.79 | 1.88 |
| MACD | 6.04 | -0.15 |
| Stochastic Oscillator | 90.66 | 13.26 |
Graham Holdings Company is a diversified holding company with operations spanning educational services, television broadcasting, healthcare, manufacturing, automotive dealerships, and other businesses. The Company's education activities are conducted through Kaplan, whose services include academic preparation programs for international students, English-language programs, exam preparation, and career and academic advisement. These services are provided to students, schools, and colleges, both domestically and outside the United States. It operates through seven reportable segments: Kaplan International, Kaplan Higher Education, Kaplan Supplemental Education, Television Broadcasting, CSI, Manufacturing and Automotive, with key revenue coming from the Education and Automotive segments.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.